Search

Your search keyword '"Younes, Anas"' showing total 2,390 results

Search Constraints

Start Over You searched for: Author "Younes, Anas" Remove constraint Author: "Younes, Anas"
2,390 results on '"Younes, Anas"'

Search Results

1. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

7. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

9. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

11. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

12. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

14. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

15. CROSSWISE Final Report Management & Entrepreneurship

16. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

17. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

18. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

20. First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors

22. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

27. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials

28. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes

29. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

30. P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)

36. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

37. OncoTree: A Cancer Classification System for Precision Oncology

38. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

40. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

41. Follicular lymphoma

45. Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

46. Figure S2 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

47. Abstract 3369: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies

48. Supplementary Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

49. Supplementary Tables from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

50. Data from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Catalog

Books, media, physical & digital resources